Embolic compositions

Patent metadata

Field	Value
Publication number	US-10368874-B2
Application number	US-201715687263-A
Country	US
Kind code	B2
Filing date	Aug 25, 2017
Priority date	Aug 26, 2016
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions.

First claim

We claim:

1. A composition comprising:
1) a biocompatible polymer formed from:
a) hydroxyethylmethacrylate monomers, or vinyl alcohol monomers, or hydroxyethylmethacrylate monomers and vinyl alcohol monomers; and
b) aromatic amine monomers;

2) a solvent; and
3) a visualization agent;
wherein the biocompatible polymer is soluble in the solvent and insoluble at physiological conditions; and
wherein the visualization agent is integrated into or associated with the biocompatible polymer, and the visualization agent is triiodophenol-lactide-glycolide (TIP).

2. The composition of claim 1 , wherein the physiological conditions include contact with a physiological fluid including blood, urine, saliva, mucous, vaginal fluid, seminal fluid, cerebral spinal fluid, sweat, plasma, bile, stomach acid, intestinal fluids, or a combination thereof.

3. The composition of claim 2 , wherein the physiological fluid has a pH of about 7.0.

4. The composition of claim 2 , wherein the physiological fluid has a pH of between about 7.0 and about 7.8.

5. The composition of claim 1 , wherein the solvent is a water miscible organic solvent.

6. The composition of claim 1 , wherein the aromatic amine monomer includes an amino group which is about 90% positively charged at a pH of 5 and about 10% positively charged at a pH of 7.

7. The composition of claim 1 , wherein the biocompatible polymer comprises hydroxyethylmethacrylate, polyvinyl pyridine (PVP), 1-vinylimidazole, 4-vinylpyridine, or a combination thereof.

8. The composition of claim 1 , wherein the biocompatible polymer includes about 60% w/w HEMA and the visualization agent includes about 40% w/w TIP.

9. The composition of claim 1 , wherein the biocompatible polymer includes about 15% w/w HEMA and the visualization agent includes about 85% w/w TIP.

10. The composition of claim 1 , wherein the solvent is water or a co-solvent of water and dimethyl sulfoxide (DMSO).

11. The composition of claim 1 , wherein the biocompatible polymer is formed from hydroxyethylmethacrylate monomers and aromatic amine monomers.

Assignees

• Microvention Inc

Inventors

• Baldwin Aaron
• Mehta Ami
• Lam Jonathan

Classifications

• A61B17/12181 Primary

  formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices · CPC title

• C08L33/14

  of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen · CPC title

• A61K49/0438

  Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol · CPC title

• A61K31/785 Primary

  Polymers containing nitrogen · CPC title

• A61B2017/00942

  hydrophilic · CPC title